New data details Medicare Advantage company’s ongoing commitment to environmental, social and governance prioritiesORANGE, Calif., July 30, 2024 (GLOBE NEWSWIRE)...
The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sourcesNEW YORK, July 30,...
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome...
Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes...
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated...
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving...
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74...
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life...
CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies...
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
Presentation to highlight statistically significant Phase 3 results of Tonmya™ for the management of fibromyalgia, including improvement in pain and...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces an exclusive digital and advanced analytics collaboration with Healthcare Outcomes...
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain...
John Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of...
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of...
SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and...
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024...
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to...
SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six...